Sarah Cargnin1, Pier Luigi Canonico1, Armando A Genazzani1, Salvatore Terrazzino2. 1. Department of Pharmaceutical Sciences and Interdepartmental Research Center of Pharmacogenetics and Pharmacogenomics, University of Piemonte Orientale "A. Avogadro," Novara, Italy. 2. Department of Pharmaceutical Sciences and Interdepartmental Research Center of Pharmacogenetics and Pharmacogenomics, University of Piemonte Orientale "A. Avogadro," Novara, Italy. Electronic address: salvatore.terrazzino@uniupo.it.
Abstract
INTRODUCTION: Despite the growing interest in circulating cell-free DNA (cfDNA), no conclusive evidence exists on the value of quantitative analysis of cfDNA for the prediction of lung cancer survival. We performed a systematic review and meta-analysis of primary studies to estimate the impact of higher baseline cfDNA levels on survival outcomes of patients with lung cancer. METHODS: A comprehensive search was performed using the PubMed, Web of Knowledge, and Cochrane databases up to March 2016. The methodologic quality of identified studies was assessed by the Newcastle-Ottawa scale. Potential sources of heterogeneity were investigated via subgroup and sensitivity analyses, while publication bias was evaluated by funnel plot and Egger's test. RESULTS: Among the 17 studies identified, 16 studies (n = 1723 patients) and 5 studies (n = 640) were included in the meta-analysis of overall survival (OS) and progression-free survival (PFS), respectively. Despite the fact that the association with PFS did not reach statistical significance (hazard ratio 1.12% [95% confidence interval 0.91-1.37), the pooled analysis for OS showed evidence of an increased risk of death in patients with higher baseline cfDNA levels (hazard ratio 1.76 [95% confidence interval 1.38-2.25]; p < 0.001). Further subgroup and sensitivity analyses confirmed this relationship, although significant between-study heterogeneity was still detected in most comparisons. The Egger's test revealed no statistical evidence of publication bias in the results. CONCLUSION: Our findings support the clinical validity of quantitative analysis of cfDNA for the prediction of lung cancer survival. Nevertheless, the establishment of a robust standardized method for determination of optimal cutoff thresholds is required to define the clinical relevance of cfDNA quantification for lung cancer management.
INTRODUCTION: Despite the growing interest in circulating cell-free DNA (cfDNA), no conclusive evidence exists on the value of quantitative analysis of cfDNA for the prediction of lung cancer survival. We performed a systematic review and meta-analysis of primary studies to estimate the impact of higher baseline cfDNA levels on survival outcomes of patients with lung cancer. METHODS: A comprehensive search was performed using the PubMed, Web of Knowledge, and Cochrane databases up to March 2016. The methodologic quality of identified studies was assessed by the Newcastle-Ottawa scale. Potential sources of heterogeneity were investigated via subgroup and sensitivity analyses, while publication bias was evaluated by funnel plot and Egger's test. RESULTS: Among the 17 studies identified, 16 studies (n = 1723 patients) and 5 studies (n = 640) were included in the meta-analysis of overall survival (OS) and progression-free survival (PFS), respectively. Despite the fact that the association with PFS did not reach statistical significance (hazard ratio 1.12% [95% confidence interval 0.91-1.37), the pooled analysis for OS showed evidence of an increased risk of death in patients with higher baseline cfDNA levels (hazard ratio 1.76 [95% confidence interval 1.38-2.25]; p < 0.001). Further subgroup and sensitivity analyses confirmed this relationship, although significant between-study heterogeneity was still detected in most comparisons. The Egger's test revealed no statistical evidence of publication bias in the results. CONCLUSION: Our findings support the clinical validity of quantitative analysis of cfDNA for the prediction of lung cancer survival. Nevertheless, the establishment of a robust standardized method for determination of optimal cutoff thresholds is required to define the clinical relevance of cfDNA quantification for lung cancer management.
Authors: Tara C Gangadhar; Samantha L Savitch; Stephanie S Yee; Wei Xu; Alexander C Huang; Shannon Harmon; David B Lieberman; Devon Soucier; Ryan Fan; Taylor A Black; Jennifer J D Morrissette; Neeraj Salathia; Jill Waters; Shile Zhang; Jonathan Toung; Paul van Hummelen; Jian-Bing Fan; Xiaowei Xu; Ravi K Amaravadi; Lynn M Schuchter; Giorgos C Karakousis; Wei-Ting Hwang; Erica L Carpenter Journal: Pigment Cell Melanoma Res Date: 2017-10-23 Impact factor: 4.693
Authors: Melina Marmarelis; Jeffrey C Thompson; Charu Aggarwal; Tracey L Evans; Erica Carpenter; Roger B Cohen; Corey J Langer; Joshua Bauml Journal: Ann Transl Med Date: 2017-09
Authors: Myung Han Hyun; Jae Sook Sung; Eun Joo Kang; Yoon Ji Choi; Kyong Hwa Park; Sang Won Shin; Sung Yong Lee; Yeul Hong Kim Journal: Oncotarget Date: 2017-10-10
Authors: Silvia R Vitale; Floris H Groenendijk; Ronald van Marion; Corine M Beaufort; Jean C Helmijr; Hendrikus Jan Dubbink; Winand N M Dinjens; Patricia C Ewing-Graham; Ramon Smolders; Helena C van Doorn; Ingrid A Boere; Els M J J Berns; Jozien Helleman; Maurice P H M Jansen Journal: Biomolecules Date: 2020-03-07